Dusting Itself Off From Restructuring, Sequenom Hopes New Service Will Help Revenue Growth | GenomeWeb

After an aborted flirtation with drug discovery and a brush with the specter of downgraded stock, Sequenom is looking for a way up and out.

Two days after CEO Toni Schuh reiterated to investors his plan to set the company on track to profitability — a move that scuttled the company’s nascent pharmaceuticals business and will cost 50 staffers their jobs by the end of the year — the San Diego-based company this week introduced what it hopes will become a new source of revenue: an assay design service.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.